Breaking Finance News

A statement released earlier today by N+1 Singer about Oxford BioMedica PLC (LON:OXB) bumps the target price to 330.00GBX

Having a price of 3.10GBX, Oxford BioMedica PLC (LON:OXB) traded 1.97% higher on the day. With the last stock price close down -32.97% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of 3.65GBX and a 200-day moving average of 4.64GBX. 1,009,050 shares of OXB traded hands, down from an average trading volume of 3,112,980

Stating a potential upside of 105.45%, N+1 Singer upped the price target of Oxford BioMedica PLC (LON:OXB) to 330.00GBX

On 8/27/2015, N+1 Singer released a statement on Oxford BioMedica PLC (LON:OXB) maintained the target price at 12.00GBX that suggested an upside of 0.41%.

Recent Performance Chart

Oxford BioMedica PLC (LON:OXB)

Oxford BioMedica PLC has 52 week low of 2.98GBX and a 52 week high of 8.45GBX and has a market capitalization of 0 GBX.

Brief Synopsis On Oxford BioMedica PLC (LON:OXB)

Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company's segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. The Company provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The Company's product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson's disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.